It is tempting to speculate that the long-lasting effects of PD-1-based immunotherapy in some, but not all, patients might be related to the development of immunotherapy-mediated monocyte differentiation and trained immunity versus generation of immunosuppressive MDSCs and TAMs during cancer-driven emergency myelopoiesis. Here, PDCD1 is linked to cancer.